Find a Clinical Trial

Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus

2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized,
Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the
Efficacy and Safety of BIIB059 in Participants with Active Subacute
Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus
Erythematosus with or without Systemic Manifestations and Refractory
and/or Intolerant to Antimalarial Therapy (AMETHYST)

18+

Learn more

Psoriasis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

18+

Learn more

Atopic Dermatitis (Eczema)

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and
older with moderate-to-severe atopic dermatitis (eczema).

12-17

Learn more

TAP Block and minimally invasive hysterectomy for pain control

A randomized, controlled, observer-blinded pilot trial of laparoscopic large volume, multisite transversus abdominal plane (TAP) block with liposomal bupivacaine in patients undergoing minimally invasive hysterectomy for endometrial cancer

18-80

Learn more

Multi-spectral imaging

Label-free, multi-scale imaging for improved detection of ovarian cancer metastases

18-99

Learn more

Non- Invasive, Label-free Detection of Cervical Pre-Cancers In vivo

Non-Invasive, Label-free Detection of Cervical Pre-Cancers In vivo

18-100

Learn more

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)

XPORT-EC-042 (GOG-3083): A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

18+

Learn more